These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 25648361)

  • 21. Anti-CD25 monoclonal antibody replacement therapy for chronic kidney disease in liver transplant recipients.
    Walsh C; Barkun J; Tchervenkov J; Deschenes M; Ghali P; Wong P; Chaudhury P; Paraskevas S; Metrakos P; Cantarovich M
    Transplantation; 2013 Feb; 95(3):495-500. PubMed ID: 23296149
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tacrolimus and Everolimus de novo versus minimization of standard dosage of Tacrolimus provides a similar renal function at one year after liver transplantation: a case-control matched-pairs analysis.
    Mocchegiani F; Montalti R; Nicolini D; Svegliati Baroni G; Benedetti A; Risaliti A; Vivarelli M
    Ann Transplant; 2014 Oct; 19():545-50. PubMed ID: 25347718
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Calcineurin inhibitor sparing in paediatric solid organ transplantation : managing the efficacy/toxicity conundrum.
    Tredger JM; Brown NW; Dhawan A
    Drugs; 2008; 68(10):1385-414. PubMed ID: 18578558
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High tacrolimus intra-patient variability is associated with graft rejection, and
    Del Bello A; Congy-Jolivet N; Danjoux M; Muscari F; Lavayssière L; Esposito L; Hebral AL; Bellière J; Kamar N
    World J Gastroenterol; 2018 Apr; 24(16):1795-1802. PubMed ID: 29713132
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Donor Age Predicts Calcineurin Inhibitor Induced Neurotoxicity After Liver Transplantation.
    Lué A; Martinez E; Navarro M; Laredo V; Lorente S; Jose Araiz J; Agustin Garcia-Gil F; Serrano MT
    Transplantation; 2019 Aug; 103(8):e211-e215. PubMed ID: 30985573
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The incidence of post-transplant cancer among kidney transplant recipients is associated with the level of tacrolimus exposure during the first year after transplantation.
    Lichtenberg S; Rahamimov R; Green H; Fox BD; Mor E; Gafter U; Chagnac A; Rozen-Zvi B
    Eur J Clin Pharmacol; 2017 Jul; 73(7):819-826. PubMed ID: 28342067
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Two yr mycophenolate mofetil plus low-dose calcineurin inhibitor for renal dysfunction after liver transplant.
    Biselli M; Vitale G; Gramenzi A; Riili A; Berardi S; Cammà C; Scuteri A; Morelli MC; Grazi GL; Pinna AD; Andreone P; Bernardi M
    Clin Transplant; 2009; 23(2):191-8. PubMed ID: 19210525
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids: a prospective study in one hundred de novo renal transplant recipients.
    Kuypers DR; Claes K; Evenepoel P; Maes B; Coosemans W; Pirenne J; Vanrenterghem Y
    Clin Pharmacokinet; 2004; 43(11):741-62. PubMed ID: 15301578
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: a randomised controlled study.
    Schlitt HJ; Barkmann A; Böker KH; Schmidt HH; Emmanouilidis N; Rosenau J; Bahr MJ; Tusch G; Manns MP; Nashan B; Klempnauer J
    Lancet; 2001 Feb; 357(9256):587-91. PubMed ID: 11558484
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of combined mycophenolate mofetil and low-dose calcineurin inhibitor therapy on renal function, cardiovascular risk factors, and graft function in liver transplant patients: preliminary results of an open prospective study.
    Beckebaum S; Cicinnati VR; Klein CG; Brokalaki E; Yu Z; Malago M; Frilling A; Gerken G; Broelsch CE
    Transplant Proc; 2004 Nov; 36(9):2671-4. PubMed ID: 15621120
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cyclosporin versus tacrolimus for liver transplanted patients.
    Haddad EM; McAlister VC; Renouf E; Malthaner R; Kjaer MS; Gluud LL
    Cochrane Database Syst Rev; 2006 Oct; 2006(4):CD005161. PubMed ID: 17054241
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus.
    Levy G; Grazi GL; Sanjuan F; Wu Y; Mühlbacher F; Samuel D; Friman S; Jones R; Cantisani G; Villamil F; Cillo U; Clavien PA; Klintmalm G; Otto G; Pollard S; McCormick PA
    Liver Transpl; 2006 Oct; 12(10):1464-72. PubMed ID: 17004259
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tacrolimus Monotherapy in Recipients of Liver Transplant: A Single-Center Experience.
    Lin SD; Lee Krishnamoorthy T; Kumar R; Lim RT
    Transplant Proc; 2019; 51(6):1920-1922. PubMed ID: 31399176
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tacrolimus Concentration/Dose Ratio is Associated with Renal Function After Liver Transplantation.
    Thölking G; Siats L; Fortmann C; Koch R; Hüsing A; Cicinnati VR; Gerth HU; Wolters HH; Anthoni C; Pavenstädt H; Suwelack B; Schmidt HH; Kabar I
    Ann Transplant; 2016 Mar; 21():167-79. PubMed ID: 27003330
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tacrolimus Drug Exposure Level and Smoking Are Modifiable Risk Factors for Early
    Vanlerberghe BTK; van Malenstein H; Sainz-Barriga M; Jochmans I; Cassiman D; Monbaliu D; van der Merwe S; Pirenne J; Nevens F; Verbeek J
    Transpl Int; 2024; 37():12055. PubMed ID: 38440132
    [No Abstract]   [Full Text] [Related]  

  • 36. Tolerability of everolimus-based immunosuppression in maintenance liver transplant recipients.
    Vallin M; Guillaud O; Morard I; Gagnieu MC; Mentha G; Adham M; Morelon E; Boillot O; Giostra E; Dumortier J
    Clin Transplant; 2011; 25(4):660-9. PubMed ID: 21158921
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sustained renal response to mycophenolate mofetil and CNI taper promotes survival in liver transplant patients with CNI-related renal dysfunction.
    Kornberg A; Küpper B; Thrum K; Krause B; Büchler P; Kornberg J; Sappler A; Altendorf-Hofmann A; Wilberg J; Friess H
    Dig Dis Sci; 2011 Jan; 56(1):244-51. PubMed ID: 20824504
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sirolimus-based immunosuppressive therapy in liver transplant recipient with tacrolimus-related chronic renal insufficiency.
    Yang YJ; Chen DZ; Li LX; Kou JT; Lang R; Jin ZK; Han DD; He Q
    Transplant Proc; 2008 Jun; 40(5):1541-4. PubMed ID: 18589147
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence, Risk Factors, and Impact of Donor-Specific Alloantibodies After Adult Liver Transplantation.
    Vandevoorde K; Ducreux S; Bosch A; Guillaud O; Hervieu V; Chambon-Augoyard C; Poinsot D; André P; Scoazec JY; Robinson P; Boillot O; Dubois V; Dumortier J
    Liver Transpl; 2018 Aug; 24(8):1091-1100. PubMed ID: 29665189
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity.
    Flechner SM; Kobashigawa J; Klintmalm G
    Clin Transplant; 2008; 22(1):1-15. PubMed ID: 18217899
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.